EBC-46 : Phase I Dose-Escalation Study to Determine the Safety and Tolerability of an Intratumoural Injection of EBC-46 in Patients with Refractory Cutaneous or Subcutaneous Tumours

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Head and neck,SkinCutaneous Squamous Cell Carcinoma (CSCC),Head and neck,Melanoma (Skin),Merkel cell,Mouth (including tonsil, tongue, soft palate, cheeks, lips, gum),Nose (nasopharynx),Oral cavity,Squamous cell carcinoma ,Throat (hypopharynx),Thyroid

Trial Overview Read MoreRead more

This phase I trial is evaluating an intratumoural injection in patients with skin cancer and cancers of the head and neck.
 

This trial is treating multiple types of cancer including skin cancer or cancers of the head and neck.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Phase I Dose-Escalation Study to Determine the Safety and Tolerability of an Intratumoural Injection of EBC-46 in Patients with Refractory Cutaneous or Subcutaneous Tumours

Commercial Sponsor

QBiotics Limited

Summary

This study aims to evaluate the safety and tolerability of a new investigational drug called EBC-46 in participants with advanced cancer. Who is it for? Patients may be eligible to join this study if aged 18 years or more and have been diagnosed with an advanced cutaneous or subcutaneous tumour. Study details: All participants in this study will receive a single EBC-46 injection directly into tumours. EBC-46 may lead to breakdown of tumour blood vessels and recruitment and activation of white blood cells. This leads to rapid tumour cell death. This drug has not previously been tested in humans. Participants will be monitored for 3 weeks following EBC-46 injection in order to evaluate safety, tolerability, tumour response and pharmacokinetics (the action of the body on the drug). The results from this study will be analysed to see if it is worthwhile for this new drug to be tested in future studies involving larger numbers of cancer participants.

Recruiting Hospitals Read MoreRead more

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next